Please login to the form below

Not currently logged in
Email:
Password:

GSK to tackle inflammatory bowel disease

GSK has exercised an option to further develop ChemoCentryx's Traficet-EN (CCX282-B) for the treatment of inflammatory bowel disease

GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialisation of Traficet-EN (CCX282-B), a specific CCR9 antagonist, which potentially offers a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease. 

The option extends two further identified backup compounds and represents the first product licensing opportunity resulting from the original collaboration with ChemoCentryx through GSK's Centre of Excellence for External Drug Discovery (CEEDD).

Under the terms of the collaboration, ChemoCentryx will receive an option exercise fee of $35m and may be eligible for further regulatory milestone payments. 

Following successful development and commercialisation of any of the candidate compounds, ChemoCentryx will receive double-digit royalties on product sales, with the ability to increase royalties by co-funding development through phase III clinical trials and co-promoting to physician specialists in North America. 

GSK will assume responsibility for the continued development of CCX282-B in patients with moderate-to-severe Crohn's disease, and potential ulcerative colitis studies will also be considered for this product candidate.

"Progressing the development of CCX282-B takes us closer to a valuable new treatment option for patients who suffer from these chronic, debilitating bowel diseases," said Moncef Slaoui, chairman of research and development, GSK. "CCX282-B may offer advantages over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients".

11th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics